• FDA Leaders, Advisory Panel Go Head-to-Head Over Aducanumab

    1 month ago - By Medscape

    FDA leaders and members of the advisory panel that recommended against approval of the controversial Alzheimer's drug aducanumab have gone head-to-head in two perspectives published today in the New England Journal of Medicine.
    Medscape Medical News
    Read more ...